Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909016 | 0.84 | RAB9A (0.43) | ALDH1A1L3MBTL1SMN1; SMN2LMNANPC1 | |
| SCHEMBL2347651 | 0.81 | NPC1 (0.42) | ALDH1A1PTGS2SMN1; SMN2LMNATSHR | |
| SCHEMBL316519 | 0.80 | RAB9A (0.41) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL1902421 | 0.79 | FAAH (0.42) | ALDH1A1L3MBTL1SMN1; SMN2LMNAHTT | |
| SCHEMBL316018 | 0.78 | KMT2A (0.46) | ALDH1A1PTGS2SMN1; SMN2LMNANPC1 | |
| SCHEMBL2900034 | 0.75 | NPC1 (0.44) | L3MBTL1SMN1; SMN2NPC1RAB9ACYP1A2 | |
| SCHEMBL4882778 | 0.74 | CYP17A1 (0.39) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL2900762 | 0.71 | HCAR1 (0.41) | NR3C1PGRMGLL | |
| SCHEMBL2350243 | 0.70 | KCNN4 (0.41) | SMN1; SMN2HPGDMEN1KMT2AMGLL | |
| SCHEMBL1908255 | 0.70 | NPC1 (0.49) | ALDH1A1L3MBTL1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342196-B1 | PYRAZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2651921-A1 | INSECTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130253011-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| EP-2197280-B1 | PYRAZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012080376-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1654244-A1 | 3-ARYL-4-HYDROXYFURANONE COMPOUNDS AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005019196-A1 | 3-ARYL-4-HYDROXYFURANONE COMPOUNDS AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | ALDH1A1 4287/4885L3MBTL1 1852/4885PTGS2 4337/4885 |
| US-20130253011-A1 | INSECTICIDAL COMPOUNDS | ACHE, CHRM1, NIT2 | ALDH1A1 118/4885L3MBTL1 654/4885PTGS2 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.